{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:16:13Z","timestamp":1790712973333,"version":"4.1.0"},"reference-count":56,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The goal of antiviral therapy is to improve the quality of life and survival of patients with chronic hepatitis B (<jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content>) by halting the progression to cirrhosis, end\u2010stage liver disease or hepatocellular carcinoma (<jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content>), thus preventing anticipated liver\u2010related death. Oral administration of potent and less resistance\u2010prone nucleot(s)ide analogues (<jats:styled-content style=\"fixed-case\">NUC<\/jats:styled-content>s), such as entecavir (<jats:styled-content style=\"fixed-case\">ETV<\/jats:styled-content>) and tenofovir disoproxil fumarate (<jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content>) has become the most popular treatment strategy worldwide because of their excellent efficacy and safety profile as well as easy management confirmed in both registration trials and in clinical practice studies. Long\u2010term administration of <jats:styled-content style=\"fixed-case\">ETV<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> suppresses <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> replication in &gt;95% of patients, resulting in biochemical remission, histological improvement including the regression of cirrhosis and prevention or reversal of clinical decompensation but not the development of <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content>, particularly in patients with cirrhosis. Moreover, <jats:styled-content style=\"fixed-case\">NUC<\/jats:styled-content>s can be administered to all patients including those with severe liver disease, the elderly and in those who do not respond, are unwilling to take or have contraindications to interferon. The need for long\u2010term, perhaps indefinite, treatment is the main limitation of <jats:styled-content style=\"fixed-case\">NUC<\/jats:styled-content>s therapy with the associated costs, unknown long\u2010term safety and the low rates of hepatitis B surface antigen (<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>sAg) seroclearance, which is still the best stopping rule for <jats:styled-content style=\"fixed-case\">NUC<\/jats:styled-content>s\u2010treated patients with cirrhosis.<\/jats:p>","DOI":"10.1111\/liv.13291","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T04:15:37Z","timestamp":1484280937000},"page":"45-51","source":"Crossref","is-referenced-by-count":71,"title":["Hepatitis B virus long\u2010term impact of antiviral therapy nucleot(s)ide analogues (<scp>NUC<\/scp>s)"],"prefix":"10.1111","volume":"37","author":[{"given":"Glenda","family":"Grossi","sequence":"first","affiliation":[{"name":"\u201cA.M. e A. Migliavacca\u201d Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Vigan\u00f2","sequence":"additional","affiliation":[{"name":"Hepatology Division Ospedale San Giuseppe Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Loglio","sequence":"additional","affiliation":[{"name":"\u201cA.M. e A. Migliavacca\u201d Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[{"name":"\u201cA.M. e A. Migliavacca\u201d Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,3]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2015.05.004"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.026"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23327"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22841"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802878"},{"key":"e_1_2_14_9_1","first-page":"A229","article-title":"Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8\u00a0year results from two phase 3 trials","volume":"60","author":"Marcellin P","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.01.044"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307023"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60757-6"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12476"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.04.037"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.5472"},{"key":"e_1_2_14_16_1","first-page":"672A","article-title":"Efficacy and safety of entecavir treatment of chronic hepatitis B patients in real\u2010world clinical practice","volume":"58","author":"Tanwandee T","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3960-x"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)61218-6"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-4027-8"},{"key":"e_1_2_14_20_1","first-page":"A933","article-title":"Four years of tenofovir monotherapy for NUC na\u00efve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis","volume":"58","author":"Lampertico P","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28438"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.008"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308435"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23785"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.11.040"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61425-1"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24361"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23952"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26301"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302024"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.033"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.045"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.006"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i40.6849"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26180"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.002"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306409"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.035"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60523-1"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60768-0"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.002"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60045-8"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.07.023"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2675"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70077-8"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13659"},{"key":"e_1_2_14_49_1","first-page":"273","article-title":"Tenofovir\u2010induced Fanconi syndrome in a patient with chronic hepatitis B monoinfection","volume":"15","author":"Conti F","year":"2016","journal-title":"Ann Hepatol"},{"key":"e_1_2_14_50_1","first-page":"512","article-title":"Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir","volume":"107","author":"Magalh\u00e3es\u2010Costa P","year":"2015","journal-title":"Rev Esp Enferm Dig"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23346"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31358-4"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3283511287"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24406"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12115"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13253"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30846-1"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T02:40:21Z","timestamp":1694659221000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":56,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/liv.13291"],"URL":"https:\/\/doi.org\/10.1111\/liv.13291","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}